8 / 19
Page 38
Notes:
conferenceseries
.com
June 19-20, 2017 Philadelphia, USA
14
th
International Conference on
Clinical and Experimental Dermatology
Volume 8, Issue 4 (Suppl)
J Clin Exp Dermatol Res, an open access journal
ISSN:2155-9554
Dermatology 2017
June 19-20, 2017
Dermatological manifestations in pediatric rheumatology patients - The era of new biological
medications
Sukesh Sukumaran
1
and
Suprakasan Sukumaran
2
1
University of Arkansas for Medical Sciences, USA
2
KIMS Medical Center, Qatar
R
heumatic diseases have a wide variety of cutaneous manifestations especially in the pediatric population. The dermatologic
manifestations may be the sole features in some of the rheumatic diseases especially at the initial presentation. The
common rheumatic diseases include the pediatric systemic lupus erythematosus, juvenile dermatomyositis, systemic onset
juvenile idiopathic arthritis, juvenile scleroderma and juvenile psoriasis. Dermatological manifestations are also seen with
less common rheumatic diseases including the periodic fever syndrome, SAPHO syndromes, Neutrophilic dermatoses and
pediatric vasculitis. The timely recognition of these rashes helps to diagnose the underlying rheumatic disease and also to start
appropriate immune modulation. With the new biological management of the rheumatic disease the challenges are higher as
initiation of the appropriate treatment within the therapeutic window will help to alleviate the long term damage to the joints
or internal organs. The biologics commonly used in pediatric rheumatology includes different anti TNF agents (etanercept,
adalimumab, infliximab), anti IL1 (anakinra, canakinumab, rilanocept), anti IL6- tocilizumab, anti B cell treatment with
rituximab and belimumab, co stimulatory inhibitors like abatacept, anti IL12/23 agent and IL17 agent like secukinumab. The
medications used to treat different rheumatic conditions lead to dermatological manifestations and implicated in the new
onset of cutaneous lupus and drug induced lupus. The topic is very important as the field of rheumatology and dermatology is
changing its face every day with the advent of new biologic medications. In this talk we are focusing on the rheumatic diseases
with cutaneous manifestations and new biologic medications.
Biography
Sukesh Sukumaran completed his Pediatric Residency from UMDNJ, Camden, NJ and Pediatric Rheumatology Fellowship from USC in Los Angeles, CA. He
attended his Medical School 21 years ago in University of Kerala, Trivandrum, India. He is currently an Assistant Professor of Pediatric Rheumatology at UAMS/
ACH. He was the Program Director for the Pediatric Rheumatology Fellowship Program at University of Florida prior to the current position. He is currently working
as the Chief Consultant at KIMS Hospital and Medical Center at Doha, Qatar. He is currently a Visiting Professor of Dermatology and Head of the Division of
Dermatology and Venereology at Palana Institute of Medical Sciences. He was the Head of the Division of Dermatology and Venereology at Trivandrum Medical
College and In-charge of the education for post-graduate & medical students and residents.
ssukumaran@uams.eduSukesh Sukumaran et al., J Clin Exp Dermatol Res 2017, 8:4 (Suppl)
DOI: 10.4172/2155-9554-C1-059